BrainStorm’s NurOwn does not have enough clinical data according to FDA  


BrainStorm Cell Therapeutics announced it recently met with senior leadership from the US Food and Drug Administration (FDA) and received feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) amyotrophic lateral sclerosis (ALS) phase III clinical trial.  

According to a press release from BrainStorm, the FDA concluded from their initial review that the current level of clinical data does not provide the threshold of substantial evidence that the FDA is seeking to support a biologics license application (BLA). In addition, the FDA advised that this recommendation does not preclude Brainstorm from proceeding with a BLA submission. 

“Brainstorm will first consult with principal investigators, ALS experts, expert statisticians, regulatory advisors, and ALS advocacy groups to assess the benefit/risk of a BLA submission before making a final decision,” said Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, New York, USA. “We want to thank our independent advisors for their candour and unwavering commitment to our ALS programme. We also would like to give a heartfelt thank you to all ALS patients and their families who were involved in this clinical research programme. The company will continue to build on the strength of its wonderful, professional, and dedicated team while being well funded at a current position of over US$40M in cash. We will soon announce our next flagship product and programme for other diseases with unmet needs.” 

“Many of us with longstanding experience in ALS therapy development agree that there was evidence of benefit from NurOwn cell therapy and hope that there will be an opportunity for further assessment of this modality in ALS,” said Robert Brown, director of the neurotherapeutics programme at the University of Massachusetts Medical School, Worcester, USA. 

“ALS is a devastating disease with worse outcomes than most forms of cancer,” said Anthony Windebank, Jean and Judith Pape Adams professor of neuroscience, Mayo Clinic College of Medicine and Science, Rochester, USA. “The clear signal in this trial that some patients with ALS respond to treatment with NurOwn is a light at the end of the tunnel. The careful study of biomarkers associated with response will help lead us forward towards a broadly effective therapy. The patients and their families who have brought us to this point are true heroes.” 

“I share my profound gratitude and thanks to the patients and families that participated in this phase III trial and all the teams at the six sites,” said Merit Cudkowicz, chief of neurology and director of the Healey & AMG Center for ALS at Massachusetts General Hospital, and the Julieanne Dorn professor of neurology at Harvard Medical School, Boston, USA. “We learned a lot about the efficacy and safety of NurOwn in people with ALS in this well conducted trial. We also learned some of the challenges with the use of ALSFRS-R at the lower end of the scale. Additional discussions with the community and sharing all the data in a peerreviewed publication are critical next steps.” 


Please enter your comment!
Please enter your name here